| 货号 | AF732-SP |
| 别名 | CD153 antigen; CD153; CD30 antigen ligand; CD30-L; CD30LCD30 ligand; CD30LGMGC138144; TNFSF8; tumor necrosis factor (ligand) superfamily, member 8; tumor necrosis factor ligand superfamily member 8 |
| 反应种属 | Mouse |
| 应用 | Western Blot(0.1 µg/mL) |
| 目标/特异性 | Detects mouse CD30 Ligand/TNFSF8 in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 5% cross‑reactivity with recombinant human CD30 Ligand is observed. |
| 使用方法 | Western Blot: 0.1 µg/mL Neutralization: Measured by its ability to neutralize CD30 Ligand/TNFSF8-induced IL‑6 secretion in the HDLM human Hodgkin’s lymphoma cell line. The Neutralization Dose (ND50) is typically 3-10 µg/mL in the presence of 500 ng/mL Recombinant Mouse CD30 Ligand/TNFSF8 and 10 µg/mL of a cross-linking antibody, Mouse polyHistidine Monoclonal Antibody. |
| 来源 | Polyclonal Goat IgG |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 944 (Human); 21949 (Mouse) |
| 纯化方式 | Antigen Affinity-purified |
| 免疫原 | Mouse myeloma cell line NS0-derived recombinant mouse CD30 Ligand/TNFSF8 Gln68-Asp239 Accession # P32972 |
| 内毒素水平 | <0.10 EU per 1 μg of the antibody by the LAL method. |
| 生物活性 | Mouse |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 背景 | CD30 Ligand (CD30L)/TNFSF8 is a type II membrane protein belonging to the TNF superfamily. CD30L is expressed on the cell surface of activated T cells, B cells, and monocytes. The protein is also constitutively expressed on granulocytes and medullary thymic epithelial cells. The specific receptor for CD30L is CD30/TNFRSF8, a type I transmembrane glycoprotein belonging to the TNF receptor superfamily. CD30 was originally identified as a cell surface antigen of Hodgkins and Reed-Sternberg cells using the monoclonal antibody Ki-1. CD30 is also expressed on different non-Hodgkins lymphomas, virus-infected T and B cells, and on normal T and B cells after activation. Among T cells, CD30 is preferentially expressed on a subset of T cells producing Th2-type cytokines and on CD4+/CD8+ thymocytes that coexpress CD45RO and IL-4 receptor. CD30 ligation by CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation and cell death by apoptosis. CD30 can act as a co‑stimulatory molecule in thymic negative selection and may also play a critical role in the pathophysiology of Hodgkins disease and other CD30+lymphomas. |
| 运输条件 | Blue Ice |
| 存放说明 | 4℃ |
| 参考文献 |
|
IL‑6 Secretion Induced by CD30 Ligand/TNFSF8 and Neutralization by Mouse CD30 Ligand/TNFSF8 Antibody. In the presence of a cross-linking antibody, Mouse polyHistidine Monoclonal Antibody (10 µg/mL, Catalog # MAB050), Recombinant Mouse CD30 Ligand/TNFSF8 (Catalog # 732-CL) stimulates IL‑6 secretion in the HDLM human Hodgkin’s lymphoma cell line in a dose-dependent manner (orange line), as measured by the Human IL‑6 Quantikine ELISA Kit (Catalog # D6050). Under these conditions, IL‑6 secretion elicited by Recombinant Mouse CD30 Ligand/TNFSF8 (500 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Mouse CD30 Ligand/TNFSF8 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF732). The ND50 is typically 3‑10 µg/mL. |
